Brown Snake Envenomation Medication

  • Author: David Cheng, MD; Chief Editor: Rick Kulkarni, MD   more...
 
Updated: Apr 20, 2011
 

Medication Summary

The antidote for systemic envenomations by the brown snake is the equine-derived antivenin. In a study of 35 patients with severe brown snake envenomation, two thirds of the cases were neutralized with 5 ampules and 89% were neutralized with 10 ampules.[2] As with all equine-derived antivenins, anaphylaxis should be anticipated and treated if any allergic reactions occur. Pretreatment with antihistamines and corticosteroids should be included.

Hypotension should be treated with isotonic crystalloid infusions and vasopressors if blood pressure is refractory to fluids alone.

Tetanus toxoid should be given when indicated.

Cholinesterase inhibitors, such as edrophonium and neostigmine, may be given to palliate the neurological sequelae of the venom but should not replace definitive airway control.

Next

Antivenin

Class Summary

Gives passive immunity to the venom and should be administered immediately if any signs of systemic toxicity are present.

Antivenin

 

According to the Antivenin Index, the monovalent form is not carried in the US but may be found in Australia (Commonwealth Serum Laboratories, Melbourne, Australia). The polyvalent antivenin may be obtained at the Bronx Zoo, but a local zoo may be contacted.

Skin testing before antivenin administration is not recommended because it may sensitize the individual to future antivenin use and will delay the administration of the antivenin. Antihistamines and subcutaneous epinephrine should be administered (if no contraindications are present) before giving the antivenin.

1 U neutralizes 0.01 mg venom in vitro.

Previous
Next

Antihistamines

Class Summary

H1 and H2 blockers should be given to prevent immune mediated responses and may be continued for an additional 5 days or for as long as symptoms persist.

Diphenhydramine (Benadryl)

 

For symptomatic relief of symptoms caused by release of histamine in allergic reactions.

Cimetidine (Tagamet)

 

H2 antagonist that, when combined with an H1 type, may be useful in treating itching and flushing in anaphylaxis, pruritus, urticaria, and contact dermatitis that do not respond to H1 antagonists alone. Use this medication in addition to H1 antihistamines.

Chlorpheniramine (Chlor-Trimeton)

 

Competes with histamine or H1-receptor sites on effector cells in blood vessels and respiratory tract.

Previous
Next

Corticosteroids

Class Summary

Should be employed when evidence of an allergy-mediated event is present. However, onset of action is approximately 4-6 h and has limited benefit in the initial acute treatment of the rapidly deteriorating anaphylactic patient. Nonetheless, corticosteroids may benefit patients with persistent bronchospasm or hypotension.

Methylprednisolone (Solu-Medrol)

 

Decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability.

Prednisone (Deltasone, Orasone, Sterapred)

 

Used for the treatment of a variety of diseases including serum sickness in the outpatient setting. Prednisone is inactive and must be metabolized to the active metabolite prednisolone. The conversion may be impaired in patients with liver disease.

Previous
Next

Bronchodilators

Class Summary

These agents have combined alpha- and beta-adrenergic agonist action and are the agents of first choice in the treatment of anaphylaxis.

An additional option in the management of persistent bronchospasm may be anticholinergic agents. These agents block the action of acetylcholine at parasympathetic sites in bronchial smooth muscle.

Epinephrine (Adrenalin, EpiPen)

 

DOC for treating anaphylactoid reactions. The alpha-agonist effects of epinephrine increase peripheral vascular resistance and reverse peripheral vasodilatation, vascular permeability, and systemic hypotension. Conversely, the beta-agonist effects produce bronchodilatation, positive inotropic and chronotropic cardiac activity, and result in an increased production of intracellular cAMP.

Albuterol (Ventolin, Proventil)

 

Beta-agonist useful in the treatment of bronchospasm that is refractory to epinephrine. Relaxes bronchial smooth muscle by action on beta 2-receptors and has little effect on cardiac muscle contractility

Theophylline (Aminophylline, Theo-Dur, Slo-bid)

 

Potentiates exogenous catecholamines. Stimulates endogenous catecholamine release and diaphragmatic muscular relaxation, which in turn stimulates bronchodilation.

For bronchodilation, near toxic (>20 mg/dL) levels are usually required.

Ipratropium (Atrovent)

 

Chemically related to atropine. Has antisecretory properties and, when applied locally, inhibits secretions from serous and seromucous glands lining the nasal mucosa.

Previous
Next

Cholinesterase inhibitors

Class Summary

May be useful in reversing neurological complications of the venom; however, they should not be a substitute for airway management.

Edrophonium (Enlon, Reversol, Tensilon)

 

Short active cholinesterase inhibitor that inhibits the destruction of acetylcholine by acetylcholinesterase and may palliate weakness. Facilitates transmission of impulses across myoneural junction and results in increased cholinergic responses (eg, miosis, increased tonus of intestinal and skeletal muscles, bronchial and ureteral constriction, bradycardia, and increased salivary and sweat gland secretions).

Usually administered IV, but, if this is not possible, IM/SC route may be used.

Neostigmine (Prostigmin)

 

Longer acting cholinesterase inhibitor that can be used when edrophonium is ineffective. Inhibits destruction of acetylcholine by acetylcholinesterase, which facilitates transmission of impulses across myoneural junction.

Previous
Next

Immune Globulin

Class Summary

Consists of administration of immunoglobulin pooled from serum of immunized subjects.

Tetanus immune globulin (TIG)

 

Used for passive immunization of any person with a wound that might be contaminated with tetanus spores.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

David Cheng, MD  Associate Professor of Emergency Medicine, Education Director, Associate Emergency Medicine Residency Director, Case Medical Center

David Cheng, MD is a member of the following medical societies: American College of Emergency Physicians, American Heart Association, Council of Emergency Medicine Residency Directors, International Society for Mountain Medicine, National Association of EMS Physicians, Society for Academic Emergency Medicine, Society of Critical Care Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Daniel J Dire, MD, FACEP, FAAP, FAAEM  Clinical Professor, Department of Emergency Medicine, University of Texas Medical School at Houston; Clinical Professor, Department of Pediatrics, University of Texas Health Sciences Center San Antonio

Daniel J Dire, MD, FACEP, FAAP, FAAEM is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American Academy of Pediatrics, American College of Emergency Physicians, and Association of Military Surgeons of the US

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD  Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

David Eitel, MD, MBA  Associate Professor, Department of Emergency Medicine, York Hospital; Physician Advisor for Case Management, Wellspan Health System, York

David Eitel, MD, MBA is a member of the following medical societies: American College of Emergency Physicians, American Society of Pediatric Nephrology, Society for Academic Emergency Medicine, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD  Attending Physician, Department of Emergency Medicine, Cambridge Health Alliance, Division of Emergency Medicine, Harvard Medical School

Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: WebMD Salary Employment

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Shaun J Chun, MD, to the development and writing of this article.

References
  1. O'Leary MA, Isbister GK, Schneider JJ, Brown SG, Currie BJ. Enzyme immunoassays in brown snake (Pseudonaja spp.) envenoming: detecting venom, antivenom and venom-antivenom complexes. Toxicon. Jul 2006;48(1):4-11. [Medline].

  2. Yeung JM, Little M, Murray LM, Jelinek GA, Daly FF. Antivenom dosing in 35 patients with severe brown snake (Pseudonaja) envenoming in Western Australia over 10 years. Med J Aust. Dec 6-20 2004;181(11-12):703-5. [Medline].

  3. Brown SG, Caruso N, Borland ML, McCoubrie DL, Celenza A, Isbister GK. Clotting factor replacement and recovery from snake venom-induced consumptive coagulopathy. Intensive Care Med. Sep 2009;35(9):1532-8. [Medline].

  4. Isbister GK, Brown SG, MacDonald E, White J, Currie BJ. Current use of Australian snake antivenoms and frequency of immediate-type hypersensitivity reactions and anaphylaxis. Med J Aust. Apr 21 2008;188(8):473-6. [Medline].

  5. Brimacombe J, Murray A. Envenomation by Ingram's Brown snake (Pseudonaja ingrami). Anaesth Intensive Care. Apr 1995;23(2):231-3. [Medline].

  6. Broad AJ, Sutherland SK, Coulter AR. The lethality in mice of dangerous Australian and other snake venom. Toxicon. 1979;17(6):661-4. [Medline].

  7. Buckley N, Dawson AH. Unusual results of brown snake envenomation. Med J Aust. Jun 21 1993;158(12):866-8. [Medline].

  8. Currie BJ. Snakebite in tropical Australia: a prospective study in the "Top End" of the Northern Territory. Med J Aust. Dec 6-20 2004;181(11-12):693-7. [Medline].

  9. Henderson A, Baldwin LN, May C. Fatal brown snake (Pseudonaja textilis) envenomation despite the use of antivenom. Med J Aust. May 17 1993;158(10):709-10. [Medline].

  10. Hodgson WC. Pharmacological action of Australian animal venoms. Clin Exp Pharmacol Physiol. Jan 1997;24(1):10-7. [Medline].

  11. Isbister GK, O'Leary MA, Schneider JJ, Brown SG, Currie BJ; ASP Investigators. Efficacy of antivenom against the procoagulant effect of Australian brown snake (Pseudonaja sp.) venom: in vivo and in vitro studies. Toxicon. Jan 2007;49(1):57-67. [Medline].

  12. Masci PP, Mirtschin PJ, Nias TN, et al. Brown snakes (Pseudonaja genus): venom yields, prothrombin activator neutralization and implications affecting antivenom usage. Anaesth Intensive Care. Jun 1998;26(3):276-81. [Medline].

  13. Munro JG, Pearn JH. Snake bite in children: a five year population study from South-East Queensland. Aust Paediatr J. Dec 1978;14(4):248-53. [Medline].

  14. Pantanowitz L, Guidozzi F. Management of snake and spider bite in pregnancy. Obstet Gynecol Surv. Oct 1996;51(10):615-20. [Medline].

  15. Ripamonti C, De Conno F, Boffi R, et al. Can somatostatin be administered in association with morphine in advanced cancer patients with pain?. Ann Oncol. Aug 1998;9(8):921-3. [Medline].

  16. Schapel GJ, Utley D, Wilson GC. Envenomation by the Australian common brown snake--Pseudonaja (Demansia) textilis textilis. Med J Aust. Jan 16 1971;1(3):142-4. [Medline].

  17. Sprivulis P, Jelinek GA. Fatal intracranial haematomas in two patients with Brown snake envenomation. Med J Aust. Feb 20 1995;162(4):215-6. [Medline].

  18. Sutherland SK. Concern over the choice of antivenom for "false king brown snake" bites and a plea for a name change. Med J Aust. Feb 15 1999;170(4):187. [Medline].

  19. Sutherland SK. Venomous Creatures of Australia. Oxford University Press; 1981.

  20. Sutherland SK, Leonard RL. Snakebite deaths in Australia 1992-1994 and a management update. Med J Aust. Dec 4-18 1995;163(11-12):616-8. [Medline].

  21. Tibballs J, Sutherland S, Kerr S. Studies on Australian snake venoms. Part 1: The haemodynamic effects of brown snake (Pseudonaja) species in the dog. Anaesth Intensive Care. Nov 1989;17(4):466-9. [Medline].

  22. Tibballs J, Sutherland SK, Kerr S. Studies on Australian snake venoms, Part II: The haematological effects of brown snake (Pseudonaja) species in the dog. Anaesth Intensive Care. Aug 1991;19(3):338-42. [Medline].

  23. Walter FG, Bilden EF, Gibly RL. Envenomations. Crit Care Clin. Apr 1999;15(2):353-86, ix. [Medline].

  24. White J. Envenoming and antivenom use in Australia. Toxicon. Nov 1998;36(11):1483-92. [Medline].

Previous
Next
 
Pseudonaja guttata (speckled brown snake).
Pseudonaja textilis (eastern brown snake).
Pseudonaja modesta (ringed brown snake).
Pseudonaja nuchalis (western brown snake).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.